SubscribeLogin
Published

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors

Summary by Intelligence360 News
Financing led by OrbiMed with co-leads Novo Holdings and Jeito Capital Strengthened by substantial contributions from Frazier Life Sciences, Longitude Capital, RA Capital, and Catalio Capital, among others Proceeds will support development of first-in-class CLDN1 targeted medicines including Phase 1/2 studies of ALE.P02 and ALE.P03 November 12, 2024 07:00 AM Eastern Standard Time BASEL, Switzerland–(BUSINESS WIRE)–Alentis Therapeutics (“Alentis”…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

MarylandMaryland
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal